I received a response from Todd on Saturday. That in itself was unusual, but appreciated. No major surprises. How could there be? Todd can't get ahead of management. I told him the only optimism I felt was that he was still working. If Todd is still there, there's a company somewhere. Here are the direct quotes with my comments:
"NUGX-are not the NuGenerex Immuno-Oncology (NGIO) shares that will be listed shortly by your company. Those are the dividend shares that someone outside the company has listed to trade."
The "shortly" time frame is anyone's guess. So is "someone". I asked who the "someone" is and how could an outside entity hijack the NGIO shares. None of this was clarified and I requested an explanation from management.
"...the activities surrounding the trading of NUGX is not from our company & I am not able to advise you on this trading"
I did not ask for trading advice regarding NUGX.
"The Corporate Structure, Valuations & Listing details of NuGenerex Immono-Oncology (NGIO) are expected soon. All corporate filings for NuGenerex Inc. (NGIO) are updated & filed as they happen
http://www.sec.gov/cgi-bin/browse-edgar?CIK=1804585
The "soon" reference is the same as the "shortly" reference above.
"Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are company, not the financial institution who facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company's stock in the context of the stock dividend."
I told Todd that I was not interested in advice from my financial advisor or online brokerage. I wanted management to address the confusion and complications created by NUGX.
Todd cited the dividend history of shares in NGIO granted to us.
"For the sake of history since Jan. 2017 when president and CEO Joe Moscato & his new team took over Generex Biotechnology Corp. & brought back more or less a dead corporation, there have been 5 corporate stock actions."
"An original 1000 to 1 rollback of GNBT stock (March 2017)"
"1 share of GNBT stock got you 20 additional shares of (GNBT) stock Dec. 3rd 2018"
"5 shares of GNBT stock got you 2 additional shares of (GNBT) stock Feb. 25 2020"
"Also 2 sets of shares dividends of NuGenerex Immuno-Oncology/Formally Antigen Express-(not yet a public traded company)"
"Shares that were settled in accounts at the aforementioned dates are entitled to shares of : NuGenerex Immuno-Oncology (Formally named Antigen Express)"
"Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology shares."
"4 (GNBT) shares got you 1 dividend share of (NGIO) Feb 26th 2019-NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet."
"5 (GNBT) shares got you 2 dividend shares of (NGIO) Feb 25th 2020-NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet."
"No shares that are tradable public shares of (NGIO) NuGenerex Immuno-Oncology have been sent out. The corporate structure is not finalized, the trading platform is not finalized."
"Yes. NuGenerex Immuno-Oncology (Formally named Antigen Express) is considered a public company today but, no publicly listed shares have been issued from the company."
"Over the past year I have heard from many shareholders that some firms do show some type of code for shares coming to shareholders-in their individual accounts. This does by individual firms for their own record of classification/accounting/itemizing of shareholders shares coming to them?"
"These are not tradable shares."
shareholders ins some cases see a number code
a company name code (sometimes different company names)
a letter/symbol code
Etc. etc"
"Some firms show these codes in shareholders' accounts and because of the time it has taken for (NGIO) to begin publicly trading, some firms over time have removed them."
I reminded Todd that NUGX shares are traded and they create daily volatility in our portfolios. Whether or not management addresses this, confusion as to the most valuable (IMO) asset of the company has been created. The promise that management and shareholders saw in NGIO has largely dissipated.
"All shareholders of record will receive their dividends."
"We work to get a Nasdaq listing, a national board listing-nothing else. Again if we were just giving away shares for the sake of giving away shares you would have had NGIO Jr. Exchange traded 24 months ago."
I'm not sure what this means.
"We work to get Generex Biotechnology back to the Nasdaq. Then firms, institutions, and the larger investor base that don't buy OTC stocks will become interested in what we are doing. That why we go to such lengths to file S-1's so we can raise institutional money leading us to become Nasdaq compliant. Why? How? They will buy & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
"That is what is being built, this is what Joe Moscato & our team is putting together."
"Our President and Chief Executive Officer Joseph Moscato will continue to update shareholder(s) as to pending acquisitions and previously discussed corporate actions. We will continue to communicate with shareholders our company's operational progress, strategic plans, and M&A activities as soon as they take place."
New Transfer Agent: http://stctransfer.com/
Securities Transfer Corporation
2901 Dallas Parkway Suite 380
Plano, TX 75093 (Ph.) 1 (469) 633-0101
Todd invites anyone to contact him at (800) 391-655 X222
In addition to my questions regarding NUGX I asked Todd why there had been no PR's since July 26th and no CC's since May 6th. If it wasn't for his responses, we wouldn't even know a company still existed. I expressed my appreciation to Todd for taking the time to send his response.
"NUGX-are not the NuGenerex Immuno-Oncology (NGIO) shares that will be listed shortly by your company. Those are the dividend shares that someone outside the company has listed to trade."
The "shortly" time frame is anyone's guess. So is "someone". I asked who the "someone" is and how could an outside entity hijack the NGIO shares. None of this was clarified and I requested an explanation from management.
"...the activities surrounding the trading of NUGX is not from our company & I am not able to advise you on this trading"
I did not ask for trading advice regarding NUGX.
"The Corporate Structure, Valuations & Listing details of NuGenerex Immono-Oncology (NGIO) are expected soon. All corporate filings for NuGenerex Inc. (NGIO) are updated & filed as they happen
http://www.sec.gov/cgi-bin/browse-edgar?CIK=1804585
The "soon" reference is the same as the "shortly" reference above.
"Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are company, not the financial institution who facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company's stock in the context of the stock dividend."
I told Todd that I was not interested in advice from my financial advisor or online brokerage. I wanted management to address the confusion and complications created by NUGX.
Todd cited the dividend history of shares in NGIO granted to us.
"For the sake of history since Jan. 2017 when president and CEO Joe Moscato & his new team took over Generex Biotechnology Corp. & brought back more or less a dead corporation, there have been 5 corporate stock actions."
"An original 1000 to 1 rollback of GNBT stock (March 2017)"
"1 share of GNBT stock got you 20 additional shares of (GNBT) stock Dec. 3rd 2018"
"5 shares of GNBT stock got you 2 additional shares of (GNBT) stock Feb. 25 2020"
"Also 2 sets of shares dividends of NuGenerex Immuno-Oncology/Formally Antigen Express-(not yet a public traded company)"
"Shares that were settled in accounts at the aforementioned dates are entitled to shares of : NuGenerex Immuno-Oncology (Formally named Antigen Express)"
"Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology shares."
"4 (GNBT) shares got you 1 dividend share of (NGIO) Feb 26th 2019-NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet."
"5 (GNBT) shares got you 2 dividend shares of (NGIO) Feb 25th 2020-NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet."
"No shares that are tradable public shares of (NGIO) NuGenerex Immuno-Oncology have been sent out. The corporate structure is not finalized, the trading platform is not finalized."
"Yes. NuGenerex Immuno-Oncology (Formally named Antigen Express) is considered a public company today but, no publicly listed shares have been issued from the company."
"Over the past year I have heard from many shareholders that some firms do show some type of code for shares coming to shareholders-in their individual accounts. This does by individual firms for their own record of classification/accounting/itemizing of shareholders shares coming to them?"
"These are not tradable shares."
shareholders ins some cases see a number code
a company name code (sometimes different company names)
a letter/symbol code
Etc. etc"
"Some firms show these codes in shareholders' accounts and because of the time it has taken for (NGIO) to begin publicly trading, some firms over time have removed them."
I reminded Todd that NUGX shares are traded and they create daily volatility in our portfolios. Whether or not management addresses this, confusion as to the most valuable (IMO) asset of the company has been created. The promise that management and shareholders saw in NGIO has largely dissipated.
"All shareholders of record will receive their dividends."
"We work to get a Nasdaq listing, a national board listing-nothing else. Again if we were just giving away shares for the sake of giving away shares you would have had NGIO Jr. Exchange traded 24 months ago."
I'm not sure what this means.
"We work to get Generex Biotechnology back to the Nasdaq. Then firms, institutions, and the larger investor base that don't buy OTC stocks will become interested in what we are doing. That why we go to such lengths to file S-1's so we can raise institutional money leading us to become Nasdaq compliant. Why? How? They will buy & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
"That is what is being built, this is what Joe Moscato & our team is putting together."
"Our President and Chief Executive Officer Joseph Moscato will continue to update shareholder(s) as to pending acquisitions and previously discussed corporate actions. We will continue to communicate with shareholders our company's operational progress, strategic plans, and M&A activities as soon as they take place."
New Transfer Agent: http://stctransfer.com/
Securities Transfer Corporation
2901 Dallas Parkway Suite 380
Plano, TX 75093 (Ph.) 1 (469) 633-0101
Todd invites anyone to contact him at (800) 391-655 X222
In addition to my questions regarding NUGX I asked Todd why there had been no PR's since July 26th and no CC's since May 6th. If it wasn't for his responses, we wouldn't even know a company still existed. I expressed my appreciation to Todd for taking the time to send his response.
7
